Epidermal growth factor receptor tyrosine kinase inhibitors

Por Ranson, M
Publicado em 2004

Targeted antitumour therapy – future perspectives

Por Ranson, M, Jayson, G
Publicado em 2005

The topology of plasminogen binding and activation on the surface of human breast cancer cells

Por Andronicos, N M, Ranson, M
Publicado em 2001

A scoping review about conference objectives and evaluative practices: how do we get more out of them?

Por Neves, Justin, Lavis, John N, Ranson, M Kent
Publicado em 2012

Cost effectiveness and cost utility of preventing trachomatous visual impairment: lessons from 30 years of trachoma control in Burma.

Por Evans, T G, Ranson, M K, Kyaw, T A, Ko, C K
Publicado em 1996

Estimates of Global and Regional Smoking Prevalence in 1995, by Age and Sex

Por Jha, Prabhat, Ranson, M. Kent, Nguyen, Son N., Yach, Derek
Publicado em 2002

CRTs — Cluster Randomized Trials or “Courting Real Troubles”: Challenges of Running a CRT in Rural Gujarat, India

Por Ranson, M. Kent, Sinha, Tara, Morris, Saul S., Mills, Anne J.
Publicado em 2006

Biomarker method validation in anticancer drug development

Por Cummings, J, Ward, T H, Greystoke, A, Ranson, M, Dive, C
Publicado em 2007

(213)Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

Por Li, Y, Rizvi, S M A, Ranson, M, Allen, B J
Publicado em 2002

Intervention complexity--a conceptual framework to inform priority-setting in health.

Por Gericke, Christian A., Kurowski, Christoph, Ranson, M. Kent, Mills, Anne
Publicado em 2005

Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.

Por Ranson, M., Andronicos, N. M., O'Mullane, M. J., Baker, M. S.
Publicado em 1998

Helping members of a community-based health insurance scheme access quality inpatient care through development of a preferred provider system in rural Gujarat

Por RANSON, M. KENT, SINHA, TARA, GANDHI, FENIL, JAYSWAL, RUPAL, MILLS, ANNE J.
Publicado em 2006

Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2

Por Allen, B J, Tian, Z, Rizvi, S M A, Li, Y, Ranson, M
Publicado em 2003

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

Por Betticher, D. C., Anderson, H., Ranson, M., Meely, K., Oster, W., Thatcher, N.
Publicado em 1995

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

Por Dean, E, Middleton, M R, Pwint, T, Swaisland, H, Carmichael, J, Goodege-Kunwar, P, Ranson, M
Publicado em 2012

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC

Por Dean, E J, Ward, T, Pinilla, C, Houghten, R, Welsh, K, Makin, G, Ranson, M, Dive, C
Publicado em 2010

Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours

Por Cheeseman, S L, Brannan, M, McGown, A, Khan, P, Gardner, C, Gumbrell, L, Dickens, D, Ranson, M
Publicado em 2000

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Por Danson, S, Ferry, D, Alakhov, V, Margison, J, Kerr, D, Jowle, D, Brampton, M, Halbert, G, Ranson, M
Publicado em 2004

Biomarkers of apoptosis

Por Ward, T H, Cummings, J, Dean, E, Greystoke, A, Hou, J M, Backen, A, Ranson, M, Dive, C
Publicado em 2008

Equitable utilisation of Indian community based health insurance scheme among its rural membership: cluster randomised controlled trial

Por Ranson, M Kent, Sinha, Tara, Chatterjee, Mirai, Gandhi, Fenil, Jayswal, Rupal, Patel, Falguni, Morris, Saul S, Mills, Anne J
Publicado em 2007